Sei Investments Co. cut its holdings in shares of Astrazeneca PLC (NYSE:AZN) by 5.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,009,286 shares of the company’s stock after selling 54,356 shares during the period. Sei Investments Co.’s holdings in Astrazeneca PLC were worth $34,844,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Intl Fcstone Inc. grew its position in Astrazeneca PLC by 146.9% during the 2nd quarter. Intl Fcstone Inc. now owns 32,549 shares of the company’s stock worth $1,110,000 after acquiring an additional 19,365 shares during the last quarter. Royal Bank of Canada grew its position in Astrazeneca PLC by 12.2% during the 2nd quarter. Royal Bank of Canada now owns 1,855,405 shares of the company’s stock worth $63,250,000 after acquiring an additional 201,885 shares during the last quarter. Assetmark Inc. grew its position in Astrazeneca PLC by 9.0% during the 2nd quarter. Assetmark Inc. now owns 208,714 shares of the company’s stock worth $7,115,000 after acquiring an additional 17,306 shares during the last quarter. Blair William & Co. IL grew its position in Astrazeneca PLC by 62.3% during the 2nd quarter. Blair William & Co. IL now owns 42,117 shares of the company’s stock worth $1,436,000 after acquiring an additional 16,174 shares during the last quarter. Finally, Buckingham Capital Management Inc. bought a new stake in Astrazeneca PLC during the 2nd quarter worth approximately $792,000. Institutional investors and hedge funds own 14.17% of the company’s stock.
A number of equities research analysts recently commented on the company. BidaskClub lowered Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Liberum Capital downgraded Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Thursday, September 14th. BNP Paribas raised Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. BMO Capital Markets reaffirmed a “buy” rating and set a $38.00 price objective on shares of Astrazeneca PLC in a report on Tuesday, November 7th. Finally, Investec raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $34.20.
Astrazeneca PLC (AZN) traded down $0.20 on Friday, hitting $32.91. 4,922,300 shares of the company were exchanged, compared to its average volume of 3,598,055. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.73 and a current ratio of 0.91. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. The company has a market cap of $83,324.70, a PE ratio of 7.85, a P/E/G ratio of 2.75 and a beta of 0.75.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.55. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 33.93%. The business had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the prior year, the company earned $1.32 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. research analysts predict that Astrazeneca PLC will post 1.93 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Astrazeneca PLC (AZN) Shares Sold by Sei Investments Co.” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/astrazeneca-plc-azn-shares-sold-by-sei-investments-co.html.
Astrazeneca PLC Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.